Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis

European Journal of Immunology

Volumn 39, Issue 1, 2009, Pages 178-191

  Kumari, Shraddha ^a   Samani, Mukesh ^a   Khare, Prashant ^a   Misra, Pragya ^a   Dutta, Sujoy ^b   Kolli, Bala Krishna ^b   Sharma, Sharad ^a   Chang, Kwang Poo ^b   Dube, Anuradha ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Porphyrinogenic mutant; Suicidal vaccination; T cell adoptive transfer; Visceral leishmaniasis

Indexed keywords

AMINOLEVULINIC ACID; GAMMA INTERFERON; IMMUNOGLOBULIN G2; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; LEISHMANIA VACCINE; CYTOKINE; PHOTOSENSITIZING AGENT; PORPHYRINOGEN; PROTOZOON ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG SAFETY; GENETIC IMMUNIZATION; HAMSTER; IMMUNOPROPHYLAXIS; INJECTION SITE REACTION; LEISHMANIA DONOVANI; LYMPHOCYTE PROLIFERATION; MALE; MUTANT; NONHUMAN; PARASITE IMMUNITY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUICIDE GENE; T LYMPHOCYTE; VISCERAL LEISHMANIASIS; ADOPTIVE TRANSFER; ANIMAL; BLOOD; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFECT; GENETICS; IMMUNOLOGY; LEISHMANIA; METHODOLOGY; MUTATION; PARASITOLOGY; PATHOLOGY; PHOTOCHEMOTHERAPY; SKIN; TRANSPLANTATION; VACCINATION;

ADOPTIVE TRANSFER; AMINOLEVULINIC ACID; ANIMALS; ANTIBODIES, PROTOZOAN; CRICETINAE; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; LEISHMANIA; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; MALE; MUTATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINOGENS; SKIN; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 60549098684     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.200838389     Document Type: Article

References (58)

1. Desjeux, P., Leishmaniasis: Current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 2004. 27: 305-318.
2. Alvar, J., Aparicio, P., Aseffa, A., Den Boer, M., Canavate, C., Dedet, J. P., Gradoni, L. et al., The relationship between leishmaniasis and AIDS: The second 10 years. Clin. Microbiol. Rev. 2008. 21: 334-359.
3. Handman, E., Leishmaniasis: Current status of vaccine development. Clin. Microbiol. Rev. 2001. 14: 229-243.
4. Sundar, S., Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health 2001. 6: 849-854.
5. Reed, S. G. and Scott, P., T-cell and cytokine responses in leishmaniasis. Curr. Opin. Immunol. 1993. 5: 524-531.
6. Melby, P. C., Tryon, V. V., Chandrasekar, B. and Freeman, G. L., Cloning of Syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis. Infect. Immun. 1998. 66: 2135-2142.
7. Garg, R. and Dube, A., Animal models for vaccine studies for visceral leishmaniasis. Indian J. Med. Res. 2006. 123: 439-454.
8. Greenblatt, C. L., The present and future of vaccination for cutaneous leishmaniasis. Prog. Clin. Biol. Res. 1980. 47: 259-285.
9. Breton, M., Tremblay, M. J., Ouellette, M. and Papadopoulou, B., Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect. Immun. 2005. 73: 6372-6382.
10. WHO/TDR, Coming Back: WHO/TDR initiative to support live attenuated vaccines. TDR News September 2005. No. 75.
11. Bretscher, P. A., Menon, J. N. and Ogunremi, O., Towards a strategy of universally efficacious vaccination against pathogens uniquely susceptible to cell-mediated attack. J. Biotechnol. 1996. 44: 1-4.
12. Daneshvar, H., Coombs, G. H., Hagan, P. and Phillips, R. S., Leishmania mexicana and Leishmania major: Attenuation of wild-type parasites and vaccination with the attenuated lines. J. Infect. Dis. 2003. 187: 1662-1668.
13. Dumas, C., Muyombwe, A., Roy, G., Matte, C., Ouellette, M., Olivier, M. and Papadopoulou, B., Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice. Infect. Immun. 2003. 71: 6499-6509.
14. Muyombwe, A., Olivier, M., Harvie, P., Bergeron, M. G., Ouellette, M. and Papadopoulou, B., Protection against Leishmania major challenge infection in mice vaccinated with live recombinant parasites expressing a cytotoxic gene. J. Infect. Dis. 1998. 177: 188-195.
15. Mendez, S., Tabbara, K., Belkaid, Y., Bertholet, S., Verthelyi, D., Klinman, D., Seder, R. A. and Sacks, D. L., Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous leishmaniasis but maintains its potency and durability. Infect. Immun. 2003. 71: 5121-5129.
16. Sah, J. F., Ito, H., Kolli, B. K., Peterson, D. A., Sassa, S. and Chang, K. P., Genetic rescue of Leishmania deficiency in porphyrin biosynthesis creates mutants suitable for analysis of cellular events in uroporphyria and for photodynamic therapy. J. Biol. Chem. 2002. 277: 14902-14909.
17. Haldar, J. P., Ghose, S., Saha, K. C. and Ghose, A. C., Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect. Immun. 1983. 42: 702-707.
18. Gifawesen, C. and Farrell, J. P., Comparison of T-cell responses in self-limiting versus progressive visceral Leishmania donovani infections in golden hamsters. Infect. Immun. 1989. 57: 3091-3096.
19. Kedzierski, L., Zhu, Y. and Handman, E., Leishmania vaccines: Progress and problems. Parasitology 2006. 133: S87-S112.
20. Titus, R. G., Gueiros-Filho, F. J., de Freitas, L. A. and Beverley, S. M., Development of a safe live Leishmania vaccine line by gene replacement. Proc. Natl. Acad. Sci. USA 1995. 92: 10267-10271.
21. Alexander, B., Lozano, C., Barker, D. C., McCann, S. H., and Adler, G. H., Detection of Leishmania (Viannia) braziliensis complex in wild mammals from Colombian coffee plantations by PCR and DNA hybridization. Acta Trop. 1998. 69: 41-50.
22. Papadopoulou, B., Roy, G., Breton, M., Kundig, C., Dumas, C., Fillion, I., Singh, A. K. et al., Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination. Infect. Immun. 2002. 70: 62-68.
23. Spath, G. F., Garraway, L. A., Turco, S. J. and Beverley, S. M., The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts. Proc. Natl. Acad. Sci. USA 2003. 100: 9536-9541.
24. Spath, G. F., Lye, L. F., Segawa, H., Sacks, D. L., Turco, S. J. and Beverley, S. M., Persistence without pathology in phosphoglycan-deficient Leishmania major. Science 2003. 301: 1241-1243.
25. Kelty, C. J., Brown, N. J., Reed, M. W. and Ackroyd, R., The use of 5-aminolaevulinic acid as a photosensitiser in photodynamic therapy and photodiagnosis. Photochem. Photobiol. Sci. 2002. 1: 158-168.
26. Brockstedt, D. G., Bahjat, K. S., Giedlin, M. A., Liu, W., Leong, M., Luckett, W., Gao, Y. et al., Killed but metabolically active microbes: A new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat. Med. 2005. 11: 853-860.
27. Uzonna, J. E., Spath, G. F., Beverley, S. M. and Scott, P., Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J. Immunol. 2004. 172: 3793-3797.
28. Selvapandiyan, A., Duncan, R., Debrabant, A., Lee, N., Sreenivas, G., Salotra, P. and Nakhasi, H. L., Genetically modified live attenuated parasites as vaccines for leishmaniasis. Indian J. Med. Res. 2006. 123: 455-466.
29. Dutta, S., Ray, D., Kolli, B. K. and Chang, K. P., Photodynamic sensitization of Leishmania amazonensis in both extracellular and intracellular stages with aluminum phthalocyanine chloride for photolysis in vitro. Antimicrob. Agents Chemother. 2005. 49: 4474-4484.
30. Scott, P., Immunologic memory in cutaneous leishmaniasis. Cell. Microbiol. 2005. 7: 1707-1713.
31. Tabbara, K. S., Peters, N. C., Afrin, F., Mendez, S., Bertholet, S., Belkaid, Y. and Sacks, D. L., Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection. Infect. Immun. 2005. 73: 4714-4722.
32. Coler, R. N. and Reed, S. G., Second-generation vaccines against leishmaniasis. Trends Parasitol. 2005. 21: 244-249.
33. Dube, A., Sharma, P., Srivastava, J. K., Misra, A., Naik, S. and Katiyar, J. C., Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG. Parasitology 1998. 116: 219-221.
34. Misra, A., Dube, A., Srivastava, B., Sharma, P., Srivastava, J. K., Katiyar, J. C. and Naik, S., Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG. Vaccine 2001. 19: 3485-3492.
35. Howard, J. G. and Liew, F. Y., Mechanisms of acquired immunity in leishmaniasis. Philos. Trans. R. Soc. London B: Biol. Sci. 1984. 307: 87-98.
36. Armijos, R. X., Weigel, M. M., Calvopina, M., Hidalgo, A., Cevallos, W. and Correa, J., Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine 2004. 22: 1320-1326.
37. Melby, P. C., Chandrasekar, B., Zhao, W. and Coe, J. E., The hamster as a model of human visceral leishmaniasis: Progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J. Immunol. 2001. 166: 1912-1920.
38. Garg, R., Gupta, S. K., Tripathi, P., Hajela, K., Sundar, S., Naik, S. and Dube, A., Leishmania donovani: Identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis. Vaccine 2006. 24: 2900-2909.
39. Scharton-Kersten, T. and Scott, P., The role of the innate immune response in Th1 cell development following Leishmania major infection. J. Leukoc. Biol. 1995. 57: 515-522.
40. Trinchieri, G., Interleukin-12: A proinflammatory cytokine with immuno-regulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 1995. 13: 251-276.
41. Kenney, R. T., Sacks, D. L., Gam, A. A., Murray, H. W. and Sundar, S., Splenic cytokine responses in Indian kala-azar before and after treatment. J. Infect. Dis. 1998. 177: 815-818.
42. Ghalib, H.W., Piuvezam, M. R., Skeiky, Y. A., Siddig, M., Hashim, F. A., el-Hassan, A. M., Russo, D. M. and Reed, S. G., Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J. Clin. Invest. 1993. 92: 324-329.
43. Vouldoukis, I., Becherel, P. A., Riveros-Moreno, V., Arock, M., da Silva, O., Debre, P., Mazier, D. and Mossalayi, M. D., Interleukin-10 and interleukin-4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation. Eur. J. Immunol. 1997. 27: 860-865.
44. Ghose, A. C., Haldar, J. P., Pal, S. C., Mishra, B. P. and Mishra, K. K., Serological investigations on Indian kala-azar. Clin. Exp. Immunol. 1980. 40: 318-326.
45. Bhowmick, S., Ravindran, R. and Ali, N., Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. Vaccine 2007. 25: 6544-6556.
46. Rodrigues, V., Jr., Da Silva, J. S. and Campos-Neto, A., Selective inability of spleen antigen presenting cells from Leishmania donovani infected hamsters to mediate specific T cell proliferation to parasite antigens. Parasite Immunol. 1992. 14: 49-58.
47. Basu, R., Bhaumik, S., Basu, J. M., Naskar, K., De, T. and Roy, S., Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: Evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J. Immunol. 2005. 174: 7160-7171.
48. Rezai, H. R., Farrell, J. and Soulsby, E. L., Immunological responses of L. donovani infection in mice and significance of T cell in resistance to experimental leishmaniasis. Clin. Exp. Immunol. 1980. 40: 508-514.
49. Convit, J., Leishmaniasis: Immunological and clinical aspects and vaccines in Venezuela. Clin. Dermatol. 1996. 14: 479-487.
50. Howard, J. G., Hale, C. and Chan-Liew, W. L., Immunological regulation of experimental cutaneous leishmaniasis. 1. Immunogenetic aspects of susceptibility to Leishmania tropica in mice. Parasite Immunol. 1980. 2: 303-314.
51. Scott, P., Natovitz, P., Coffman, R. L., Pearce, E. and Sher, A., Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J. Exp. Med. 1988. 168: 1675-1684.
52. Jarecki-Black, J. C., Glassman, A. B. and James, E. R., Adoptive transfer of vaccine-induced resistance to Leishmania donovani. Am. J. Trop. Med. Hyg. 1985. 34: 1095-1097.
53. Ulczak, O. M., Ghadirian, E., Skamene, E., Blackwell, J. M. and Kongshavn, P. A., Characterization of protective T cells in the acquired response to Leishmania donovani in genetically determined cure (H-2b) and noncure (H-2d) mouse strains. Infect. Immun. 1989. 57: 2892-2899.
54. Polley, R., Stager, S., Prickett, S., Maroof, A., Zubairi, S., Smith, D. F. and Kaye, P. M., Adoptive immunotherapy against experimental visceral leishmaniasis with CD8+ T cells requires the presence of cognate antigen. Infect. Immun. 2006. 74: 773-776.
55. Garg, R., Gupta, S. K., Tripathi, P., Naik, S., Sundar, S. and Dube, A., Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani. Clin. Exp. Immunol. 2005. 140: 149-156.
56. Lowry, O. H., Rosebrough, N. J., Farr, A. L. and Randall, R. J., Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951. 193: 265-275.
57. Ding, A. H., Nathan, C. F. and Stuehr, D. J., Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J. Immunol. 1988. 141: 2407-2412.
58. Voller, A., Bidwell, D. E. and Bartlett, A., The Enzyme Linked Immunosorbent Assay (ELISA): A Guide with Abstracts of Microplate Application, Fileroline Press, Guernsey, CI 1979.